Analyst Ratings for Coherus Biosciences (CHRS) [Neutrals]
CHRS Rating Summary
CHRS Price Target Summary
- Highest: $14.00 (Citi)
- Lowest: $7.00 (Barclays)
- Average: $8.75
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$8.75 (+351%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 80%
Avg. $ Target:
$8.75 (+351%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 80%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/8/2023 | Maxim Group | Jason McCarthy | Downgrade | Hold (Buy) |
N/A (N/A) |
2.47 (1.94) |
-21.46% | Details |
| 3/7/2022 | JPMorgan » Updated 5/25/2023 |
Chris Schott | Downgrade | Neutral (Overweight) |
8.00 (9.00) |
11.56 (1.94) |
-83.22% | Details |
 |
||||||||
